0.13Open0.13Pre Close0 Volume2 Open Interest2.50Strike Price0.00Turnover837.01%IV61.84%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.0515Delta0.0238Gamma47.77Leverage Ratio-0.0810Theta0.0000Rho-2.46Eff Leverage0.0006Vega
Black Diamond Therapeutics Stock Discussion
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and gli...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics presented promising clinical data on its lead candidate BDTX-1535 at the 2024 ASCO Annual Meeting. The Phase 1 dose escalation trial in recurrent glioblastoma (GBM) patients showed a favorable safety profile and encouraging anti-tumor activity, with sev...
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
No comment yet